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Bifunctional inhibitors of the trypsin-like activity of eukaryotic 
proteasomes 
Gtinther Loidl, Michael Groll, Hans-Jiirgen Musiol, Lars Ditzel, Robert Huber 
and Luis Moroder 
Background: The 20s proteasome is a multicatalytic protease complex that 
exhibits trypsin-like, chymotrypsin-like and post-glutamyl-peptide hydrolytic 
activities associated with the active sites of the p2, p5 and /31 subunits, 
respectively. Modulation of these activities using inhibitors is essential for a 
better understanding of the proteasome’s mechanism of action. Although there 
are highly selective inhibitors of the proteasome’s chymotryptic activity, inhibitors 
of similar specificity have not yet been identified for the other activities. 
Results: The X-ray structure of the yeast proteasome reveals that the sidechain 
of Cysll8 of the p3 subunit protrudes into the S3 subsite of the p2 active site. 
The location of this residue was exploited for the rational design of bidentated 
inhibitors containing a maleinimide moiety at the P3 position for covalent linkage 
to the thiol group and a carboxy-terminal aldehyde group for hemiacetal 
formation with the Thrl hydroxyl group of the active site. Structure-based 
modelling was used to determine the optimal spacing of the maleinimide group 
from the P2-Pl dipeptide aldehydes and the specificity of the Sl subsite was 
exploited to limit the inhibitory activity to the p2 active site. X-ray crystallographic 
analysis of a yeast proteasome-inhibitor adduct confirmed the expected 
irreversible binding of the inhibitor to the P3 subsite. 
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Conclusions: Maleoyl-P-alanyl-valyl-arginal is a new type of inhibitor that is 
highly selective for the trypsin-like activity of eukaryotic proteasomes. Despite 
the reactivity of the maleinimide group towards thiols, and therefore the limited 
use of this inhibitor for in vitro studies, it might represent an interesting new 
biochemical tool. 
Introduction 
The proteasome is a multicataly-tic proteinase complex 
that is responsible for the intracellular protein turnover in 
prokaryotes and eukaryotes. This cellular function is 
linked to the protein degradation pathway that requires 
ubiquitin and ATP, involving the 26s proteasome in 
which the core and proteolytic chamber is formed by the 
ZOS proteasome. The proteasome removes abnormal, mis- 
folded or improperly assembled proteins from the cell and 
it is involved in the stress response, cell-cycle control, cell 
differentiation and metabolic adaptation to the cellular 
immune response [l-8]. 
The determination of the crystal structure of the 20s pro- 
teasome from Sac&zro~~~~~ cert&% reveals that the 28 
protein subunits are arranged as a (al-a7, pl--~7J2 
complex consisting of four stacked rings [9]. l’hrec of the 
seven different p subunits are fully processed during 
assembly and maturation of the protein with release of the 
amino-terminal nucleophile, Thrl, in the active sites of 
the pl, 82 and /% subunits. Mutational studies in yeast 
have shown that these three p subunits are responsible for 
the three major proteolytic activities of the eukaryotic pro- 
teasome against small chromogenic substrates and a large 
protein, respectively [lo-121, that is? pl for the post-glu- 
tamyl peptide hydrolytic (PGPH). PZ for the trypsin-like 
and BS for the chymotrypsin-like activity. 
Specific modulation of these activities with reversible and 
irreversible inhibitors is essential for a better understand- 
ing of the mechanism of action of this enzyme in substrate 
degradation and thus in cytosolic protein breakdown. For 
this purpose, various reversible and irreversible synthetic 
inhibitors have been proposed (for a recent review, see 
[13]). Besides the known peptidyl c@‘-epoxyketone [14], 
peptidyl chloromethyl ketone and peptidyl diazomethyl 
ketone irreversible inhibitors [lS], 3.4dichloroisocoumarin 
[16,17] was found to to react covalently with Thrl in the 
active site 18,191 and the microbial natural product lacta- 
cystin [ZO] was shown to react with the same site via its 
active r/aJto-lactacystin-P-lactone intermediate [21,22]. 
Although lactacystin still exhibits partial inhibition of both 
the PGPH and trypsin-like activities [20,23], significantly 
more selective inhibitors for the chymotrypsin-like activity 
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were obtained with peptidyl vinylsulfones [24,25]. For a 
reversible inhibition of mammalian proteasomes, a series of 
peptide aldehydes and peptide boronic acids was synthe- 
sized, with the main focus on the chymotrypsin-like activity 
(for a recent review? see [26]). Cross-reaction of the syn- 
thetic inhibitors with other proteases is known to occur, but, 
surprisingly, even the natural product lactacystin was found 
to inactivate cathepsin A as well as the proteasome [27]. 
Previous studies determined that the treatment of mam- 
malian [Z&29] and yeast [12] proteasomes with large 
excesses of the thiol reagent N-ethylmaleinimide (NEM) 
leads to selective inhibition of the trypsin-like activity. 
Because of the high reactivity of NEM, at least 17 sites 
per enzyme particle were found to be modified, so the 
experiments did not identify the essential residues for the 
proteolytic activity. The crystal structure of yeast 20s pro- 
teasome revealed that a cysteine residue is located near to 
the B2 active site, Cys118 of the B3 subunit, which pro- 
trudes with its sidechain into the S3 subsite of this active 
site [9]. This cysteine residue is conserved among the 
known primary structures of the B3 subunits of eukaryotic 
proteasomes; the observed inactivation of the trypsin-like 
activity of the mammalian and yeast proteasomes might, 
therefore, indeed derive from the chemical modification 
of this thiol function if recognition and binding of the sub- 
strate is prevented by the cyclic N-ethyl-succinimidylthio 
moiety in the S3 subsite. 
In the present study, we have analyzed the possibility of 
exploiting the Cysl18 thiol function for the development 
of new inhibitors that selectively address the active site of 
the B2 subunit and, therefore, its trypsin-like activity. We 
had to use the crystal structure of yeast proteasome [9] as a 
basis for’ the design of these inhibitors, because no struc- 
tural data of the mammalian proteasomes are available so 
far. ,4s outlined schematically in Figure 1, the cysteine 
residue in the S3 subsite was used to anchor peptide alde- 
hyde inhibitors via a thiol-reactive ‘handle’ in close proxim- 
ity to’the Thrl residue of the p2 active site for inactivation 
of the amino-terminal nucleophile by a covalent hemiacetal 
bond. With this inhibitor design, the basic principle of mul- 
tivalency [30,31] was applied in a new version, in which 
specific recognition of peptide aldehydes adapted in their 
structure to the S subsites leads to a covalent grafting near 
the active site and therefore to an increase in the concentra- 
tion around the active site to values that could make the 
inhibition practically irreversible. 
Results 
Structure-based design of maleinimide-functionalized 
peptide aldehydes 
The mode of binding of the peptide aldehyde Ac- 
Leu-Leu-Nle-H (where Nle = norleucine) to the active- 
site of the BZ subunit via hemiacetal linkage to the 0~ of 
Thrl is well established by the X-ray structure of the yeast 
Figure 1 
S3 subsite --+ t Sl subsite 
A schematic representation of the S subsites of the p2 active site of 
the yeast 20s proteasome as derived from the X-ray structure of the 
Ac-Leu-Leu-Nle-H/proteasome adduct [9] with maleoyl-palanyl- 
dipeptide aldehydes as potential inhibitors. 
proteasome-inhibitor adduct 191. We used this structure for 
modelling experiments in which the Ac-Leu moiety of the 
bound inhibitor was deleted and replaced by a malein- 
imide group as the thiol-reactive handle. This group was 
positioned as a P3 residue into the S3 subsite in interacting 
distance from the Cysll8 thiol function. From the kinetic 
point of view, upon recognition and binding of the Pl-P2 
moiety by the active site, the reaction of the maleinimide 
group with the Cysll8 thiol should occur immediately, if a 
spacer of the correct size and properties is used. The ethyl- 
ene moiety was selected as the spacer (Figure 1) because it 
was predicted that, as ethylene is relatively small, it would 
restrict the movements of the maleinimide group but allow 
the rotational motion required for an optimal adaptation to 
the reactive thiol group. Because of the unique location of 
Cys118 in the S3 subsite of p2, such maleoyl-peptide alde- 
hydes should act as classical reversible inhibitors at the 81 
and B.5 active sites with affinities related mainly to the 
sidechain properties of residues Pl and P2. The aldehydes 
exert a strong inactivation of the 02 active site, however, if 
the,spacer of the bound dipeptide unit allows the malein- 
imide to react with with the thiol group or oice ne7sa if for- 
mation of the succinimidylthio group allows optimal fitting 
of the dipeptide unit into the Sl-S2 subsites. 
Synthesis of maleoyl-B-alanyl-dipeptide aldehydes 
For a detailed analysis of the inhibition of the three major 
activities of the proteasome by maleinimide-functionalized 
dipeptide aldehydes, the three compounds listed in Table 1 
were synthesized. For the synthesis of the maleoyl-B-alanyl- 
dipeptide aldehyde derived from the calpain inhibitor I, 
Mal-PAla-Leu-Me-H (Z), we made use of the intermediate 
H-Leu-Nle-Sc from our previously reported synthesis of 
Ac-Leu-Leu-Nle-H (1) [32] with the aldehyde protected 
as semicarbazone (SC). Reaction with Mal-PAla-OSu (where 
OSu = N-hydroxysuccinimide ester) [33] followed by mild- 
acid treatment in presence of formaldehyde to drive the 
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Table 1 
Synthetic maleoyl-&alanyl-dipeptide aldehydes as potential 
inhibitors of the 82 active site of eukaryotic proteasomes. 
Inhibitor Structure 
Mal-PAla-Leu-Nie-H (2) 
Mal-PAla-Val-Lys-H (3) 
Mal-PAla-Val-Arg-H (4) 
semicarbazone hydrolysis to completion, led to compound 2 
as an analytically well-characterized product. 
For the synthesis of the peptide aldehydes 3 and 4, 
Z-Lys(Boc)-OH and Z-Arg(Adoc),-OH were converted to 
the corresponding Weinreb amides that were then 
reduced with LiAIH, to produce the related aldehydes, as 
outlined in Figure 2. These were protected as diethyl 
acetals for the further amino-terminal elongation steps to 
the dipeptides and finally to the maleoyl derivatives. 
Upon acid treatment of the fully protected intermediates, 
the maleoyl-B-alanyl-dipeptide aldehydes 3 and 4 were 
isolated as hydrochloride and trifluoroacetate, respec- 
tively, and as stable compounds upon storage in the cold. 
Inhibition of yeast proteasome with maleoyl-dipeptide 
aldehydes 
To compare the inhibitory potencies of maleoyl-B-alanyl- 
dipeptide aldehydes with inactivation by the simple thiol 
reagent NEM, the yeast proteasome was incubated with 
NEM at concentrations ranging from 1 pM to 1 mM. As 
expected from previous findings in mammalian [Z&29] and 
yeast [12] proteasomes, the PGPH and chymotrypsin-like 
activities are not affected by NEM at concentrations up to 
100 /&I (data not shown). Conversely, as shown in 
Figure 3a, incubation of the proteasome with 1 @I or 
10 @I NEM leads to a time-dependent weak, but well- 
detectable reduction of the trypsin-like activity. At 100 @I 
and, in an even more pronounced manner, at 1 mM NEM 
concentration significantly faster inactivation is observed 
which reaches a plateau value of approximately 10% resid- 
ual activity after 1 h and 40 min incubation, respectively. 
These results are in full agreement with earlier findings 
[l&28,29]. The residual activity of about 10% may be 
Figure 2 
z-x-on 
1, HN(OMe) Me; HOBt; TBTU; DIEA 
2. LiAIH, /ether 
3. EtOH / HCI 
4.H,;PdiC 
1 
H-X-DEA X = Lys(Boc) or Arg(Adoc) 2 
1 Z-Val-OSu 
2. H,;Pd/C 
3. MalspAla-0% 
4. add 
V = Lys, Arg 
Mal-PAla-I/al-V-H 
Chemistry 8 Biology 
Synthesis of maleoyl-kalanyl-dipeptide aldehydes. 
attributed to partial access of the substrate to the S3- 
blocked 02 active site. More probable, however, is the non- 
specific cleavage of the trypsin-substrate at the other two 
active sites of the multicatalytic protease, as a residual 
trypsin-like activity of 1.5% was also determined for a BZ 
subunit Thrl-+Ala mutant of yeast proteasome [lo]. This 
would suggest that at high concentrations NEM is capable 
of inactivating the active site of the BZ subunit almost com- 
pletely by modifying the adjacent CysllX residue of the B3 
subunit. Although maleinimides are known for their very 
fast and quantitative reaction with thiols [34,35], the slow 
and highly concentration-dependent kinetics of inactiva- 
tion can only be explained by a strongly impeded diffusion 
of the reagent into the inner chamber of the proteasome. 
Ac-Leu-Leu-Nle-H inhibits the chymotryptic activity of 
the yeast proteasome with high potency (IC,, = 2.1 PM) 
and very weakly inhibits both the PGPH and trypsin-like 
activities (Table 2). Correspondingly, both the potency and 
the time course of inactivation of the yeast proteasome by 
the related maleoyl compound 2 were expected to be 
similar to that by NEM. As shown in Figure 3b, at just 
100 @I concentration of compound 2 the trypsin-like activ- 
ity is, however, totally blocked after 30 min incubation. 
When crystals of the proteasome from Thermop~asma aci- 
dophihm [36] and S. cereuisiae [9] are soaked with 5mM 
calpain inhibitor I. all active sites are occupied by the 
tripeptide aldehyde, confirming the relatively unspecific 
substrate, and therefore inhibitor, recognition properties of 
the single active sites of the proteasomes. This unspecific 
recognition of the maleoyl-dipeptide aldehyde 2 by the BZ 
active site could explain the significantly higher inactivation 
potency of this compound than that of NEM. Moreover, at 
100 pM concentration inhibitor 2 apparently competes very 
efficiently with the trypsin substrate Bz-Phe-Val-Arg-AMC 
(where AMC = 7-amido-4-methyl-coumarin) for binding to 
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Figure 3 
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Time dependency of inhibition of yeast proteasome by (a) NEM, (b) Mal$Ala-Leu-Nle-H (2), (c) Mal-PAla-Val-Lys-H (3), (d) Mal-PAla-Vat-Arg-H 
(4) at 1 PM (W), 10 PM (O), 100pM (A) and 1 mM (W. 
the pl and fi.5 sites, thus leading to the quantitative sup- 
pression of substrate hydrolysis. ,4s expected from the 
inhibitory properties of Ac-Leu-Leu-Nle-H (Table 21, the 
related compound 2 does not inhibit the proteasome’s 
PGPH activity, but surprisingly it doesn’t even inhibit the 
chymotryptic activity when these activities are measured 
with the ‘specific’ substrates Z-Leu-Leu-Glu-PNA and 
Sue-Leu-Leu-Val-Tyr-AMC. respectively. Replacement 
of the Ac-Leu portion of the calpain inhibitor-I with the 
Mal-PAla moiety therefore strongly reduces the affinity of 
the inhibitor for the fi.5 chymotryptic site. The strong effect 
of hydrophobic P3 residues on inhibition of the chymotryp- 
tic activity of the proteasome is well established [37]. The 
time dependency of inactivation of the yeast proteasome by 
Mal-@Ala-Leu-Nle-H (Z), shown in Figure 3b, raises the 
question of whether or not peptidic compounds penetrate 
the proteasome barrel faster than even smaller, but nonpep- 
tidic compounds like NEM because there is such a weak 
recognition of the Leu-Nle-H moiety by the subsites of the 
PZ active site to direct the reaction of the maleoyl group 
with CysllS of the S3 subsite. 
Conversely, the incorporation of a basic residue into posi- 
tion Pl of the dipeptide aldehyde moiety was expected to 
greatly facilitate this recognition process and thus also 
facilitate binding to the 02 active site. Indeed the inactiva- 
tion potency of Mal-PAla-Val-Lys-H (3) is significantly 
enhanced, with an IC,, value of 3.1 PM (Table 2), com- 
pared with compound 2 (IC,,, = 13 phi). With 10 @I 
inhibitors, the trypsin-like activity is switched off and the 
time course of inactivation (Figure 3c) again shows full 
Table 2 
Inhibition of the PGPH, trypsin- and chymotrypsin-like 
activities of yeast proteasome by maleoyl-fl-alanyl-dipeptide 
aldehydes. 
Inhibitor PGPH Trypsin-like Chymotrypsin-like 
Ac-Leu-Leu-Nle-H >I00 >lOO 2.1 
Mal-PAla-Leu-Nle-H >lOO 13 >lOO 
Mal-PAla-Val-Lys-H >lOO 3.4 > 100 
Mal-PAla-Val-Arg-H >lOO 0.5 >lOO 
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Figure 4 
Model and electron-density map of the yeast 20s proteasome/Mal- 
PAla-Val-Arg-H (4) adduct. The electron density map was calculated 
with phases of the free enzyme structure and contoured around the 
inhibitor molecule at 2s cutoff. The model parts are marked with 
different colours for their carbon atoms: green for p2, white for p3 and 
yellow for the inhibitor. 
inactivation after about 30 min incubation at inhibitor con- 
centrations higher than the IC,,, value, indicating that this 
time interval is related to the slow k,, rate of the inhibition 
process, which is dominated by the hampered diffusion 
into the proteasome barrel. 
By replacing the lysine with arginine as Pl residue, an 
additional improvement in the inhibitory potency 
(IC,, = 0.5 @l) is observed and, within the limits of error 
of the assay system, again about 30 min are required for full 
inactivation of the proteasome (Figure 3d). Given that a 
loo-fold dilution of the inhibited enzyme was not restoring 
trypsin-like activity, the working assumption of a covalent 
linkage of the inhibitor to Cysl18 was confirmed. 
The presence of three active sites of limited substrate 
specificity and the difficult access of molecules into the 
inner chamber of the barrel-shaped multicacalytic protease 
make kinetic evaluation of the inhibition data difficult and 
complex [38]. Moreover, in the present case irreversible 
linkage of the inhibitors in the pros-position to the active 
site and reversible hemiacetal linkage of the aldehyde to 
the active-site Thrl adds further complication. The 
inhibitory potencies of the maleoyl-p-alanyl-dipeptide 
aldehydes were therefore compared with each other in 
terms of the ICj, values that were determined for the 
PGPH, chymotrypsin- and trypsin-like activities (Table 2). 
X-ray structure of the proteasome-inhibitor 4 adduct 
The binding mode of this new class of inhibitors was 
determined using X-ray structural aaalysis of the yeast pro- 
teasome-inhibitor 4 adduct at 2.5 .4 resolution. As shown 
in Figure 4, the electron-density map of the crystals 
soaked with Mal-PAla-Val-Arg-H is well-defined and 
clearly depicts the structure of the inhibitor bound to the 
PZ active site. The pl and PS active sites are not occupied 
by this inhibitor, in contrast to Ac-Leu-Leu-Kle-H, 
which, in crystals of the yeast proteasome, is bound to all 
three active sites. The latter finding is in full agreement 
with the low inhibition of the chymotrypsin-like and 
PGPH activities of the proteasome by Mal-PAla-C’al- 
Arg-H. The inhibitor is covalently linked at the carboxyl 
terminus to the Oy of Thrl via hemiacetal bond formation, 
whereby the resulting hydroxyl group is hydrogen bonded 
to the backbone CO of Gly17. The arginine sidechain is 
deeply inserted into the Sl pocket forming a salt bridge 
between the guanidino group and the carboxylate of 
Glu.53. This interaction is reinforced by the Asp28 car- 
boxylate and by an additional hydrogen bond to the car- 
bony1 oxygen of Ala32 The sidechain of Glu53 is visibly 
shifted from its original position to form the salt bridge. 
\i’aline was selected as the P2 residue, in analogy to the 
substrate used to measure the inhibition of the trypsin-like 
activity; although already from the X-ray structure of the 
proteasome/,4c-Leu-Leu-We-H adduct it was known that 
the S2 subsite is shallow and does not have particular 
binding preferences 191. The sidechain of valine as the PZ 
residue points to the bulk water and a hydrogen-bonding 
network is established between the peptide backbone of 
the inhibitor and the substrate-binding cleft of the @? 
active site. In fact, the valine CO and NH are hydrogen 
bonded to Thr21 NH and CO. respectively. and the 
p-alanine CO to 4la49 NH. The S-K distance was mea- 
sured after manual fitting of the inhibitor into the electron- 
density map calculated from the model of the enzyme. 
The S-&Z distance is 2.15 A and therefore reasonably 
close to the distance of a single S-C bond (1.82 A), which 
indicates covalent thiosuccinimidyl linkage of the inhibitor 
to CysllX of the 83 subunit. The thiol addition to the 
maleinimide double bond occurs at only one of the two 
possible carbon atoms in the defined R-configuration, and 
the resulting thiosuccinimidyl ring is held into juxtaposi- 
tion by hydrogen-bonding interactions between the imido 
group and the Se20 hydroxyl function, and between the 
succinimide carbonyl distal to the thioether bond and the 
sidechain amide of GlnZ2. Given that a well-defined elec- 
tron-density map was even obtained for the ethylene 
spacer? its motion is apparently highly restricted indicating 
an optimal length and sufficient flexibility to place the 
maleinimide group into interacting distance with the cys- 
teine thiol for adduct formation. 
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Discussion 
Lactacystin, a microbial natural product, irreversibly 
inhibits the chymotrypsin-like activity of mammalian pro- 
teasomes [ZO]. The X-ray structure of the yeast protea- 
some-lactacystin adduct revealed the presence of this 
inhibitor covalently linked via an ester bond to the 0~ of 
Thrl in the p.5 active site, where a dense network of 
hydrogen bonds and hydrophobic interactions hold the 
molecule in position to allow its high degree of selectivity 
[9]. The chymotrypsin-like activity is completely switched 
off with lactacystin, but partial inhibition of the PGPH 
and tryptic activities is also observed [20,23]. Very 
recently, attempts have been made to develop selective 
peptidyl vinylsulfone inhibitors [24,25]. A high degree of 
selectivity was obtained for the p5 active site, whereas 
selective inhibition of the pl and PZ active sites was less 
successful. Conversely, the maleoyl dipeptide aldehyde 
Mal-PAla-Val-Arg-H (4) exclusively inactivates the &? 
active site of the proteasome and therefore the associated 
trypsin-like activity switched off. 
The inactivation potencies of the maleoyl-dipeptide alde- 
hydes were found to depend strongly upon the sidechain 
of the carboxy-terminal amino acid aldehyde. This finding 
supports the specific recognition of this portion of the mol- 
ecule by the enzyme Sl subsite; conversion to the hemiac- 
eta] is the primary event, followed by juxtaposition of the 
maleinimide group at the S3 subsite for reaction with the 
thiol function of Cysll8 and therefore for irreversible 
grafting of the inhibitor to this active site. This mechanism 
of inactivation could also explain why, in contrast to NEM, 
the X-ray structure revealed only one such molecule 
bound to the proteasome, despite the presence of multiple 
accessible cysteine residues and the soaking of the crystals 
with a loo-fold excess of the maleoyl compound 4. 
Significance 
Eukaryotic proteasomes are involved in the degradation 
of a multitude of proteins and peptides and therefore 
only a limited substrate specificity characterizes their 
active sites in the pl, p2 and PS subunits responsible for 
the post-glutamyl-peptide hydrolytic, trypsin-like and 
chymotrypsin-like activities, respectively. This makes 
substrate-based design of selective inhibitors extremely 
diff%ult. The unique location of a cysteine residue, 
Cysll8 of p3, in pros-position to the active site of the p2 
subunit of yeast proteasome was used for the design of a 
new type of inhibitor based on the covalent linkage of 
peptide aldehydes to the thiol function. A fully selective 
inactivation of the p2 active site of the yeast proteasome 
was achieved by exploiting the trypsin-like preference of 
the Sl subsite for basic residues and the high reactivity 
of maleinimide towards thiols. Given that Cysl18 is 
highly consewed among the known primary structures 
of mammalian proteasomes, the new inhibitor could rep- 
resent a powerful new tool for studying the mechanism 
of substrate degradation of these complex proteases. The 
only limitation for the use of this inhibitor is that it 
shows reactivity towards all types of thiols. 
Materials and methods 
All solvents and reagents used in the synthesis were of the highest 
quality commercially available, and when required were further purified 
and dried by standard methods. Thin-layer chromatography (TLC) silica 
gel 60 plates were from Merck AG (Darmstadt, Germany) and com- 
pounds were visualized with the chlorine/tolidine or permanganate 
reagent. Analytical high-performance liquid chromatography (HPLC) 
was performed on Nucleosil 1 OO/C18 columns (Macherey-Nagel, 
D&en, Germany) using linear gradients of MeCN/2% H,PO, from 5:95 
to 80:20 (A) or MeCN12% H,PO, from 30:70 to 80:20 (B) in 30 min. 
Preparative HPLC was carried out on Nucleosil RP 18 (Macherey 
Nagel, D&en, Germany) with linear gradients of MeCN/water from 5:95 
to 50:50 in 90 min. Fast-atom bombardment (FAB)-MS spectra were 
recorded on a Finnigan MAT 900 and matrix-assisted laser desorption 
ionization-time-of-flight (MALDI-TOF)-MS on a Bruker Relflex III-TOF 
MS (Bruker-Franzen, Bremen, Germany). 
The substrates Z-Leu-Leu-Glu-PNA, Bz-Phe-Val-Arg-AMC and Suc- 
Leu-Leu-Val-Tyr-AMC were purchased from Bachem (Heidelberg, 
Germany). Proteasome from S. cerevisiae was prepared as described 
previously [91 and the synthesis of Ac-Leu-Leu-Nle-H (1) and H-Leu- 
Nle-Sc trifluoroacetate was reported elsewhere 1321. 
Synthesis Mal-PAla-Leu-Nle-H (2) 
Ma/-p/a-Leu-N/e-SC. To a solution of H-Leu-Nle-Sc trifluoroacetate 
(90 mg; 0.23 mmol) and diisopropylethylamine (DIEA) (39 PI; 
0.23 mmol) in 1 ml dimethylformamide (DMF) was added Mal-PAla-OSu 
[33] (66 mg; 0.25 mmol) in 1 ml DMF. After 20 h stirring at room tem- 
perature the solvent was removed under reduced pressure and the 
residue distributed between AcOEt and water. The aqueous phase was 
extracted twice with AcOEt and the combined organic layers were 
washed with 5% KHSO,, 5% NaHCO, and water, and dried over 
MgSO,. Evaporation of the solvent gave white crystals; yield: 68 mg 
(690/o); TLC (CHCIJBrOH, 8:l) R, 0.6; HPLC (gradient A): t, 20.1 min. 
Ma/-@4/a-Leu-N/e-/-/. Mal-PAla-Leu-Nle-Sc (65 mg; 0.15 mmol) was 
dissolved in a mixture of 3 ml MeOH, 0.6 ml AcOH and 0.6 ml of 37% 
formaldehyde. After 2.5 h the solvent was evaporated and the oily 
residue was purified by preparative HPLC. Fractions containing pure 
product were collected and lyophilised; yield: 14 mg (25%); HPLC 
(gradient A): tR 16.2 min; FAB-MS: m/z=380 [M+H+]; M,=379.2 
calc’d for C,SH,,N,O,. 
Synthesis of Mal-PAla-Val-Lys-H (3) 
Z-Lys(Bocl-NfO!Jejne. To Z-Lys(Boc)-OH (6.07 g; 16 mmol), TBTU 
(5.12 g; 16 mmol), HOBt (2.15 g; 16 mmol) and DIEA (2.73 ml; 
16 mmol) in 100 ml CH,CI, was added at O’C HN(OMe)Me (1.71 g; 
18 mmol) and DIEA (2.99 ml; 18 mmol) in 50 ml CH,CI,. After 15 h 
stirring at room temperature the solvent was evaporated and the 
residue distributed between AcOEt and 5% KHSO,. The aqueous 
layer was extracted twice with AcOEt and the combined organic layers 
were washed with 5% KHSO,, 5% NaHCO, and water. The solution 
was dried over MgSO, and after removal of the solvent a yellowish oil 
was obtained; yield: 6.37 g (94%); TLC (AcOEtlpetroleum ether, 2:l): 
R, 0.7; HPLC (gradient A): t, 27.3 min; FAB-MS: m/z= 424 [M+H+l; 
M, = 423.2 calc’d for Cz, H33N306. 
Z-Lys(Eioc)-H. To an ice-cold solution of Z-Lys(Boc)N(OMe)Me (3.36 g; 
7.8 mmol) in 90 ml of dry argon saturated ether, LiAIH, (0.38 g; 10 mmol) 
was added in small portions. After stirring at room temperature for 1 h the 
mixture was cooled again to O’C, and the reaction was quenched with 
0.1 M HCI (55 ml). The aqueous phase was extracted twice with methyl 
feti-butyl ether and the combined organic layers were washed with 5% 
KHSO,, 5% NaHCO, and water, and dried over MgSO,. The solution 
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was taken to dryness; yield: 2.57 g (95%) of yellowish oil; TLC 
(AcOEtipetroleum ether, 2:l): R,O.8; HPLC (gradient A): tR24.4min; 
FAB-MS: m/z=385 [M+H+]; M,= 364.2 calc’d for C,,H,,N,O,. 
Z-Lys(Boc)-EA. Z-Lys(Boc)-H (2.74 g; 7.5 mmol) was dissolved 
under an argon atmosphere in 40ml of 0.5% HCI in dry EtOH at 
-40°C. After 20 h at 4’C sodium acetate (3 g; 38 mmol) was added 
followed by 100 ml water. The solution was concentrated to 50 ml and 
extracted with AcOEt. The combined organic layers were washed with 
water, dried over MgSO, and evaporated. The crude product was 
chromatographed on silica gel with petroleum ether/AcOEt (3:2). Upon 
concentration of the pure fractions and precipitation with hexane the 
product was obtained as white needles; yield: 2.2Og (67%); TLC 
(AcOEtIpetroleum ether, 1 :I): R, 0.8; HPLC (gradient A): t, 29.8 min; 
FAB-MS: m/z = 439 [M+H+l; M, = 438.3 calc’d for C,,H,,N,O,. 
H-Lys(Boc)-DEA. Z-Lys(Boc)-DEA (1 .O g; 2.3 mmol) was hydro- 
genated in 100 ml of 95% MeOH over Pd/C (10%). After 1 h the cat- 
alyst was filtered off and the filtrate evaporated to give a colourless oil; 
yield: 0.55 g; (79%); TLC (CHCI$MeOH/AcOH; 3:l :O.l): R, 0.7; 
HPLC (gradient A): t, 17.7 min; FAB-MS: m/z=305 [M+H+]; 
M,= 304.2 calc’d for C,,H,,N,O,. 
Z-l/al-Lys(Boc)-DEA. Z-Val-OH (0.52 g; 1.7 mmol), EDC (0.31 g; 
1.6 mmol), HOBt (0.243 g; 1.8 mmol) and DIEA (0.28 ml; 1.8 mmol) 
were dissolved in 10 ml DMF, and at O’C a solution of H-Lys(Boc)-DEA 
(0.52 g; 1.7 mmol) in 5 ml DMF was added. After stirring overnight at 
room temperature the solvent was removed and the residue distributed 
between AcOEt and 5% KHSO,. The organic layer was washed with 
5% KHSO,, 5% NaHCO, and water, and dried over MgSO,. The solu- 
tion was concentrated to small volume and the product was precipitated 
with hexane; yield: 0.789 (85%) of white crystals; TLC (CHCI,/ 
MeOH/AcOH; 14:l:O.l): R,O.6; HPLC (gradient A): tR 29.3 min; FAB- 
MS: m/z= 538 [M+H+]; M, = 537.3 calc’d for C,sH,,N,O, 
H-l/a/-LysfBo~J-DEA. Na-Deprotection was performed as described for 
H-Lys(Boc)-DEA and the product was isolated by precipitation from 
AcOEt with diisopropyl ether; yield: 0.43 g (75%) of white crystals; TLC 
(CHCIs/MeOH/AcOH, 14:l :O.l): R, 0.4; HPLC (gradient A): t, 20.5 min; 
FAB-MS: m/z= 404 [M+H+]; M, = 403.3 calc’d for C,,H,, N,O,. 
Ma/-DA/a-Val-Lys(Boc)-DEA. To a solution of H-Val-Lys(Boc)-DEA 
(0.21 g; 0.51 mmol) in 2 ml DMF Mal-PAla-OSu (0.15 g; 0.56 mmol) 
was added and the reaction mixture was worked up as described for 
Mal-PAla-Leu-Nle-Sc. The product was precipitated from AcOEt with 
hexane; yield: 0.20 g (71%); TLC (CHCI,/MeOHIAcOH, 14:l :O.l): 
R, 0.8; HPLC (gradient A): t, 24.7 min; FAB-MS: m/z= 555 [M+H+l; 
M, = 554.3 calc’d for C,,H,,N,Os. 
Ma/-PA/a-Val-Lys-HxHCl. Mal-PAla-Val-Lys(Boc)-DEA (75 mg; 
0.14 mmol) was reacted in 3 ml MeCN with 3 M HCI (3 ml) at 0°C for 
1 h. Then the solvent was removed and the crude product purified by 
preparative HPLC. Fractions containing pure product were collected 
and lyophilised; yield: 23 mg (41 %I; TLC (CHCI,/MeOH/AcOH, 
1:l :O.l): bO.4; HPLC (gradient A): t, 6.2 min; FAB-MS: m/z=381 
[M+H+]; M,= 380.2 calc’d for C,sH,,N,O,. 
Synthesis of Ma/-DA/a-Val-Arg-H(4) 
Z-ArgfAdoc),-DEA. The Weinreb amide was obtained as described 
for Z-Lys(Boc)-N(OMe)Me (yield: 97%; TLC (CHCIJMeCNIAcOH, 
1O:l :O.l): F?, 0.7; HPLC (gradient B): t, 26.6 min) and then reduced 
to the aldehyde as reported for Z-Lys(Boc)-H [yield: 97O/o; TLC 
(CHCIsIMeCNIAcOH, 1O:l :O.l) R, 0.8; HPLC (gradient B): 
t, 25.3 min]. Protection of the aldehyde was performed as described 
for the Lys derivative; yield: 69%; TLC (petroleum ether/AcOEt, 10:3): 
R, 0.7; HPLC (gradient B): t, 29.7 min; MALDI-TOF-MS: m/z= 723 
[M+H+]; M,= 722.4 calc’d for C,,H,,N,O,. 
Ma/-PA/a-Va/-Arg(Adoc),-DEA. The title compound was synthesized 
as described for the related Lys derivative in 44% yield over the four 
steps; TLC (CHCI,IMeOHIAcOH, 15:l :O.l): R, 0.4; HPLC (gradient 
B): t, 26.5 min. 
Ma/-PA/a-Val-Arg-HxTFA. Mal-PAla-Val-Arg(Adoc),-DEA (75 mg; 
0.09 mmol) was dissolved in 95% TFA. After 1 h methyl terf-butyl ether 
was added, the precipitate collected by centrifugation and purified by 
preparative HPLC. Fractions containing pure product were pooled and 
lyophilised to give a white powder; yield: 12 mg (32%); TLC 
(CHCIJMeOHIAcOH, 1 :l :O.l): R, 0.8; HPLC (gradient A): t, 8.8 min; 
FAB-MS: m/z=409 [M+H+l; M,= 408.2 calc’d for C,sH,,N,O,. 
Proteasome assay 
For the determination of IC,, values a solution of yeast proteasome in 
Tris buffer (pH 7.5; 450 ~1; 6.67 nM for PGPH, 5.56 nM for trypsin-like 
and 1 .l 1 nM for chymotrypsin-like activity) was incubated at 37°C with 
the inhibitors at varying concentrations. After 1 h 5 pl of a 0.2 M solu- 
tion of mercaptoethanol was added followed by the fluorogenic sub- 
strates for PGPH (Z-Leu-Leu-Glu-PNA, 40 PM), trypsin-like (Bz-Phe- 
Val-Arg-AMC, 8 PM) and chymotrypsin-like (Suc-Leu-Leu-Val-Tyr- 
AMC, 8 PM) assays. The substrates were previously dissolved in the 
same Tris-buffer with a minimum amount of DMSO, and the final 
volume of the samples was 500 pl. Fluorescence excitation/emission 
wavelengths were 360 nm1460 nm for AMC and 355 nm/410 nm for 
PNA. The rates of hydrolysis were monitored by the fluorescence 
increase and the initial linear portions of curves (100-300 s) were 
used to calculate the IC,, values. 
The experimental procedure for measuring the time-dependency of inhi- 
bition of the trypsin-like activity was performed as described above, 
except that the incubation time of the enzyme with the inhibitors was 
varied from 2 to 120 min. 
X-Ray structure analysis 
Crystals of 205 proteasomes from S. cereevisiae were grown in hanging 
drops at 24’C as described previously 191. The protein concentration 
used for crystallization was 40 mglml in 10 mM Tris-HCI (pH 7.5) and 
1 mM EDTA. The drops contained 4 pl protein and 2 pl reservoir solu- 
tion with 30 mM magnesium acetate, 100 mM morpholino-ethane-sul- 
phonic acid (pH 6.5) and 11% MPD. The final inhibitor concentration 
was 5 mM and crystals were soaked for 12 h. 
The space group belongs to P2, with cell dimensions of a = 134.72 A, 
b = 300.51 A, c = 144.25 A and p = 112.91’. Data to 2.5 A were col- 
lected using synchrotron radiation with h = 1 .l A on the BWG-beam- 
line at the DESY-Centre/Hamburg/Germany. Crystals were soaked in a 
cryoprotecting buffer (30% MPD, 28 mM magnesium acetate, 100 mM 
morpholino-ethane-sulfonic acid (pH 6.9) and frozen in a stream of cold 
nitrogen gas at 90 K (Oxford Cryo Systems). X-ray intensities were 
evaluated by using the MOSFILM program package (version 5.3) and 
data reduction was performed with CCP4. The anisotropy of diffraction 
was corrected by an overall anisotropic temperature factor by compar- 
ing observed and calculated structure amplitudes using the program 
X-PLOR [39]. A total of 863058 reflections yielding 345223 unique 
reflections (96.1% completness) was collected. The corresponding 
R-merge was 6.4% at 2.5 A resolution (26.9% for the 2.6-2.5 8, reso- 
lution shell). Electron density was averaged 10 times over the twofold 
noncrystallographtc symmetry axis using the program package MAIN 
[40]. Conventional crystallographic rigid body, positional and tempera- 
ture factor refinements were carried out with XPLOR using the yeast 
20s proteasome structure [91 as starting model. Model building was 
carried out with the program FRODO [411. The structure was refined 
to a R-factor of 24.4% (free R-factor= 29.2%) with rms-deviations 
from target values of 0.011 A for bonds and 1.395” for angles 1421. 
Modelling experiments were performed using the coordinates of yeast 
20s proteasome with MAIN [401. 
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